Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018
LA JOLLA, Calif., Oct. 22, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical data regarding RGLS4326, a single stranded, chemically modified oligonucleotide in clinical development for Autosomal Dominant Polycystic Kidney Disease (ADPKD), at the American Society of Nephrology's (ASN) Kidney Week 2018 meeting being held October 23-28, 2018 in San Diego, CA.
Poster Presentations: October 25, 2018, 10:00AM-12:00PM
- Abstract 3022832: Discovery and Preclinical Characterization of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Abstract 3021589: Efficacy of RGLS4326 in Human Primary ADPKD 3D-Cyst Cultured Cells.
- Abstract 3021851: RGLS4326 Confers Efficacy and Modulate Aberrant Signaling and Metabolic Pathways in PKD Mouse Models.
"We are pleased to be making several presentations on our RGLS4326 program during this year's Kidney Week meeting that we believe further demonstrate the compound's novel mechanism and therapeutic potential to treat patients with ADPKD," said Jay Hagan, President and Chief Executive Officer of Regulus.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in La Jolla, CA. For more information, please visit http://www.regulusrx.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain goals and objectives (including with respect to the development and therapeutic potential of its RGLS4326 program in ADPKD). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View original content to download multimedia:http://www.prnewswire.com/news-releases/regulus-to-present-preclinical-data-supporting-rgls4326-as-a-novel-therapeutic-in-development-for-autosomal-dominant-polycystic-kidney-disease-at-asns-kidney-week-2018-300735419.html
SOURCE Regulus Therapeutics Inc.